Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 5;24(15):12471.
doi: 10.3390/ijms241512471.

Role of microRNAs in Chronic Lymphocytic Leukemia

Francesco Autore  1 , Alice Ramassone  2 , Luca Stirparo  1 , Sara Pagotto  2   3 , Alberto Fresa  1 , Idanna Innocenti  1 , Rosa Visone  2   3 , Luca Laurenti  1   4
Affiliations
Review

Role of microRNAs in Chronic Lymphocytic Leukemia

Francesco Autore et al. Int J Mol Sci. .

Abstract

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults, with a highly variable clinical course. Improvement in the knowledge of the molecular pathways behind this disease has led to the development of increasingly specific therapies, such as BCR signaling inhibitors and BCL-2 inhibitors. In this context, the emerging role of microRNAs (miRNAs) in CLL pathophysiology and their possible application in therapy is worth noting. MiRNAs are one of the most important regulatory molecules of gene expression. In CLL, they can act both as oncogenes and tumor suppressor genes, and the deregulation of specific miRNAs has been associated with prognosis, progression, and drug resistance. In this review, we describe the role of the miRNAs that primarily impact the disease, and how these miRNAs could be used as therapeutic tools. Certainly, the use of miRNAs in clinical practice is still limited in CLL. Many issues still need to be solved, particularly regarding their biological and safety profile, even if several studies have suggested their efficacy on the disease, alone or in combination with other drugs.

Keywords: CLL; microRNA; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of mechanisms deregulated by microRNAs in Chronic Lymphocytic Leukemia (Created with Biorender.Com).
See this image and copyright information in PMC

References

    1. Ghia P., Ferreri A.M., Galigaris-Cappio F. Chronic Lymphocytic Leukemia. Crit. Rev. Oncol. Hematol. 2007;64:234–246. doi: 10.1016/j.critrevonc.2007.04.008. - DOI - PubMed
    1. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Döhner H., Hillmen P., Keating M.J., Montserrat E., Rai K.R., et al. Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Report from the International Workshop on Chronic Lymphocytic Leukemia Updating the National Cancer Institute-Working Group 1996 Guidelines. Blood. 2008;111:5446–5456. doi: 10.1182/blood-2007-06-093906. - DOI - PMC - PubMed
    1. Zenz T., Mertens D., Küppers R., Döhner H., Stilgenbauer S. From Pathogenesis to Treatment of Chronic Lymphocytic Leukaemia. Nat. Rev. Cancer. 2010;10:37–50. doi: 10.1038/nrc2764. - DOI - PubMed
    1. Eichhorst B., Dreyling M., Robak T., Montserrat E., Hallek M. Chronic Lymphocytic Leukemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2011;22:vi50–vi54. doi: 10.1093/annonc/mdr377. - DOI - PubMed
    1. Till K.J., Pettitt A.R., Slupsky J.R. Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase δ but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells. J. Immunol. 2015;194:2439–2446. doi: 10.4049/jimmunol.1402304. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources